Close communication between oncologists and dermatologists can help to avoid unnecessary dose reduction or treatment discontinuation and identify situations when treatment cessation is truly warranted.
Adverse events (AEs) following intravesical bacillus Calmette-Guérin (BCG) therapy are directly related to reduced compliance, leading to treatment cessation and incomplete treatment.
Previous research, however, has found that a significant proportion of patients do not respond to traditional CBT or exhibit residual symptomatology at treatment cessation.
Early protocol treatment cessation was also more frequent in those age ≥ 65 years (50%) versus < 65 years (35.9%) across trials.
The model also considered treatment cessation for each treatment arm, which was extrapolated in the same manner as survival, as well as the probability of progression to AML.
Uncertainty in the survival and treatment cessation variables was analyzed by incorporating the covariance generated in the survival models [20, 21].
In addition, logistic regression was used to assess factors predictive of definitive anticancer treatment cessation, and the final model was defined using a stepwise method.
Hence, HIV-HCV patients treated with LDV/SOF show significant improvement of their health-related quality of life and other patient-reported outcomes during treatment and after treatment cessation.
In 413 HIV/HCV-coinfected patients with a virologic response sustained for 12 weeks after treatment cessation, most PRO scores improved (change, up to +7.6%; P <.0001), similar to findings for HCV-monoinfected patients.
The log-normal distribution was used for survival data, a Weibull distribution for treatment cessation, a beta distribution for utilities and AE and a normal distribution for dosing and resource use [20, 21].
All patients presented with hematuria with the presentation of symptoms occurring anywhere from mid-chemotherapy treatment to as far as 60 days following treatment cessation in patients with chemotherapy-induced cystitis.
